Pelthos Therapeutics Inc.PTHS

Pelthos Therapeutics Inc. (PTH S) is a commercial-stage biopharmaceutical company betting its future on ZELSUVMI, a topical gel for molluscum contagiosum, a highly contagious viral skin infection that disproportionately affects children. The company’s latest 10-Q filing for the quarter ending March 31, 2026, shows revenue of $10.9 million, but that sum is dwarfed by a net loss of $10.2 million and an operating loss of $13.1 million. Cash and equivalents stood at $32 million, down from $35.1 million in shareholders’ equity, while inventory ballooned to $23.4 million. The company’s lead product, ZELSUVMI, generated $10.7 million in net sales in Q1 2026, a 17% quarter-over-quarter increase, but the product’s success hasn’t yet translated into profitability.

Pelthos describes itself as a company ‘committed to commercializing innovative therapeutic products for unmet patient needs,’ and its pipeline is indeed narrow but focused. ZELSUVMI is the first and only prescription therapy approved for at-home use by patients, parents, and caregivers to treat molluscum contagiosum, a condition that causes pearly, flesh-coloured bumps on the skin and is notoriously contagious. The product launched in July 2025 and has since generated $26.9 million in net sales across its first three quarters of commercial operations. The company’s pitch to investors hinges on this single product, with CEO Scott Plesha scheduled to present at the Jefferies Global Healthcare Conference on July 29, 2026, followed by one-on-one investor meetings.

The company’s financials are a study in contrasts. Revenue from contracts with customers (excluding assessed tax) was $10.9 million for the quarter, up from $7.4 million in the same period last year. Net income attributable to the parent was $-10.2 million, while operating income (loss) was $-13.1 million. Cash and cash equivalents stood at $32 million, with $145.4 million in total assets and $110.3 million in liabilities. Shareholders’ equity was $35.1 million, and diluted earnings per share were $-3.09, based on 3.3 million weighted average shares outstanding. The company spent $194,000 on property, plant, and equipment, and $186,000 on research and development, while reducing inventory by $156,000.

For a deeper look at the company’s financials and operational metrics, SEC filings are the primary source. The most recent 10-Q provides a granular breakdown of revenue, losses, cash, and inventory, while company facts and submissions JSON files offer structured data on filings and financials. The product’s commercial success is documented in press releases, including the May 28, 2026 announcement of the Jefferies conference appearance and the May 14, 2026 release detailing ZELSUVMI’s revenue growth. The separation agreement with former executive Francis Knuettel II, dated May 15, 2026, and the CBIZ dismissal letter from May 18, 2026, add colour to the company’s governance and operational shifts.

The company’s story is simple: one product, one market, and a balance sheet that’s still learning to walk. The tension lies in whether ZELSUVMI’s commercial momentum can outpace the company’s cash burn and whether the board’s recent housekeeping-including the dismissal of its auditor-will stabilise the financials or merely add noise. The next catalyst is the Jefferies conference on July 29, 2026, where Plesha will present the company’s case. If the product’s growth stalls or the burn rate accelerates, the file will need to reckon with a different story. Until then, Pelthos is a company in waiting, with a product that works and a ledger that doesn’t.